Abstract: A method for preparing a stable gatifloxacin composition in oral dosage form, said method comprising: (a) mixing gatifloxacin or a pharmaceutically acceptable salt or hydrate thereof, a disintegrant, and a filler for a time sufficient to form a mixture; (b) compacting the mixture of Step (a) at a compaction force of about 1 kN to about 30 kN for a time sufficient to form a compact; (c) milling the compact of Step (b) to form a granulation; and (d) mixing the granulation of Step (c) with an effective amount of a lubricant for a time sufficient to produce a gatifloxacin composition having a tap density of at least about 0.50 g/mL.

Abstract: A pharmaceutical composition comprising a hydrophobic matrix comprised of paroxetine HCl and a lipid component is provided. The matrix also preferably contains hydrophilic polymers, e.g., hypromellose. This invention also relates to a method of making such a composition by melt granulating paroxetine HCl with a molten binder comprising a lipid component. This invention also relates to tablets which contain such a matrix as a core and which having an enteric coating surrounding said core.

Abstract: A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from about 0.1:1 to about 25:1. The pharmaceutical composition exhibits rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.

Abstract: A pharmaceutical composition comprising microtablets, wherein said microtablets comprise lansoprazole, a lubricant, optionally one or more excipients, and an enteric coating, wherein the weight ratio of lansoprazole to lubricant is from about 1:4 to about 8:1, wherein said microtablets have a tablet size of about 1 mm to about 4 mm, and a tablet weight of 1 to 50 mg, and said microtablets are free of a separating or intermediate layer between the lansoprazole and enteric coating.